ABSTRACT
INTRODUCTION
Malaria is a life-threatening disease caused by Plasmodium parasites transmitted to people through malaria vectors. About three million peoples die and five million have been reported to be infected with malaria annually worldwide.
1 Absence of any effective malarial vaccine, chemotherapy plays crucial role in containment of the disease but unfortunately, drug-resistant strains of Plasmodium such as P. vivax have appeared against most of antimalarial introduced till date. Thus increased efforts in antimalarial drug discovery are urgently needed. The goal must be to develop safe and affordable new drugs to counter the spread of malaria parasites that are resistant to existing agents. The malaria parasite resides primarily with in the host erythrocyte, where it exploits host cell components to meet its needs for life-cycle development and degrade the haemoglobin content of infected erythrocyte cells leading to anaemia especially in children and pregnant women.
2, 3 Tetrahydrofolate, is a coenzyme involved in amino acid and nucleotide metabolism. In Plasmodium, it can be synthesized either via a de novo or salvage pathway. Dihydrofolate reductase is one of the important folate pathway enzyme used as traditional antimalarial targets. Unlike in mammalian cells these enzymes exist in malaria parasites as bi-functional enzymes. It catalyzes the NADPH-dependent reduction of H 2 folate to H 4 folate, a necessary co-factor for the biosynthesis of thymidylate, purine nucleotides, and certain amino acids. 4 1,2,4-Triazole and 2,3-disubstituted quinazoline-4(3H)-one analogs are studies against DHFR and shown that it increases the potential activity against malarial.
5, 6 Some of the most widely used antimalarial drugs inhibit folate metabolism such as sulfonamides and sulfones, usually combined with pyrimethamine or biguanides (DHFR inhibitors). Unfortunately, emergence of resistance against these drugs malaria chemotherapy and prevention has been hampered. It has been reported that resistance is determined by mutations, which do not have the same effect on all antifolates. This offers some hope for development of new DHFR inhibitors. 4 On the basis of above discussion DHFR may represent a potential target for malaria. Parthenium hysterophorus is a terrestrial weed found all around the world. P. hysterophorus confers many health benefits such as remedy for skin inflammation, rheumatic pain, diarrhoea, urinary tract infections, dysentery and neuralgia. Beside these several studies reported the anti-malarial potential of different parts of this plant. Parthenin is the major active phytoconstituents of P. hysterophorus leaf, stem flower and root. 7 Due to this we used different analogs of parthenin like compounds to target P. vivax DHFR enzyme in the present in silico study. In silico screening approach is the leading technique for preliminary identification of novel inhibitors for target proteins and predicting their biological binding mode. The majorities of anti-malarial drugs are small molecules designed to bind, interact and modulate the biological activity of the different pathogen proteins. Molecular docking inheres of three key consecutive goals; pose prediction, virtual screening and binding affinity evaluation. Computer aided drug designing is being exploited to identify hits, pick leads and optimize leads i.e. transform biologically active compounds into good drugs by enhancing their physicochemical, pharmaceutical and ADME\T (absorption, distribution, metabolism, excretion and toxicity) properties. Thus in silico modeling is used considerably to minimize risk, time and resource requirements of chemical synthesis and biological in vitro and in vivo testing. 8 In the present study we used Maestro 9.6 Schrodinger software to dock eighty five parthenin like compounds with malaria parasite and human DHFR protein. Furthermore QikProp application of Maestro 9.6 was used to predict ADME/T properties of best-docked analogs.
MATERIALS AND METHODS

Selection of Ligand and Protein molecules
GLIDE based molecular docking protocol adapted from our previous published literature with minor modifications.
9 ( Figure 1 ). Selected ligand dataset for the study are given in Table 1 . PubChem molecules having molecular weight of <500 Da were screened in this study. Recommended values of estimated number of hydrogen bonds that would be accepted by the solute from water molecules in an aqueous solution was <10. For hydrogen bonds that would be donated by the solute to water molecules in an aqueous solution was <5. Averages values are taken over a number of configurations, so they can be non-integer. All selected ligands were subjected to Ligprep wizard application of the Maestro 9.6 (Schrödinger Inc). Ligprep performs many corrections on the ligands, such as the addition of hydrogens, 2D to 3D conversion, corrected bond lengths and bond angles, low energy structure, stereochemistries and ring conformation. Ten tautomer's generated per ligands by using Maestro 9.6. The X-ray crystal structure of DHFR, PDB: 2BL9.
10 DHFR PDB: 1KMS.
11 retrieved from the protein data bank. Maestro Continued... 
-dione e* (3aR, 6S, 6aS, 9aR, 9bR)-8-heptyl-6a-hydroxy-6, 9a-dimethyl-3-methylidene-2H, 3H, 3aH, 4H, 5H, 6H, 6aH, 9H, 9aH, 9bH-azuleno [4, 5- 9.6 protein preparation wizard application performed for the correction of raw PDB structure; these are the addition of hydrogen atoms, assigning bond orders and bond length, creation of disulphide bonds, fixing of the charges and orientation of groups were included in to the protein molecules.
Molecular docking
Molecular docking studies using the chosen ligand molecules were conducted using Maestro 9.6. 12 Each of these compounds was docked into protein molecules, and the docking conformation possessing the lowest energy was fixed. After preparation of ligands and protein, optimized potential for liquid simulations (OPLS_2005) force field applied for local energy minimization (bond stretching energy) and geometry optimization.
13,14,15
After the execution OPLS_2005, a receptor-grid file was generated. Van der Waal radii of receptor atom by 1.00 Å and a partial atomic charge of 0.25 scaled for the generation of the receptor grid and consequently molecular docking was performed.
ADME/T properties studies
The majority of drug doesn't accomplish something in clinical trials due to deprived ADME/T properties. Therefore, in silico ADME/T (Absorption, Distribution, Metabolism, Excretion and Toxicity) predictive tools that could eliminate inappropriate compounds, before invested valuable time and money in primary testing of compounds. Computer based theoretical approaches transpire to be the best option for prediction of ADME/T, for new compounds. Thus, ADME/T properties of best-docked compounds were predicted using QikProp application of Maestro 9.6. ADME/T properties are prerequisite for the drug discovery and development process.
16,17
RESULTS AND DISCUSSION
Analysis of docking results of promising compounds for Plasmodium vivax DHFR
Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance in complex with inhibitors have been reported, which provide information about the exact location and composition of inhibitor binding pocket and opportunity to use the enzyme in a functional conformation. 10 We used X-ray structure of Plasmodium vivax DHFR in complex inhibitor (PDB id code 2BL9) for the docking study. Pyrimethamine (Pyr) targets dihydrofolate reductase of Plasmodium vivax (PvDHFR) as well as other malarial parasites, but its use as antimalarial is hampered by the widespread high resistance. Our selected dihydrofolate reductase of Plasmodium vivax structural insights suggest a general approach for developing new generations of antimalarial DHFR inhibitors that, by only occupying substrate space of the active site, would retain binding affinity with the mutant enzymes.
10 Molecular docking was performed using the extra precision (XP) mode of grid-based ligand docking with energetics (GLIDE). We also used known DHFR inhibitors for the comparison of results (Table 2, Figure 2 ). Our result highlighted that; CID3467446, (6R, 6aS, 9bR)-6a-hydroxy-3-(hydroxymethyl)-6, 9a-dimethyl-4H, 5H, 6H, 9bH-azuleno [4, 5- (Table 2) . Moreover, these compounds do not have better Gscore against human DHFR. Most of the interactions made by compounds with residues in active site of Plasmodium vivax DHFR seem to be hydrophobic in nature. Proteinligand interactions of 2BL9 with compounds showed that amino acids Leu136, Ile155, and Val178 appeared in the hydrophobic interactions. Furthermore, amino acids Arg115, Leu136, Lus138, and Gly175 involved in back-bone hydrogen bonding of protein-ligand interactions ( Figure 3) Interaction Modes between the parthenin like compounds and human DHFR Molecular docking of Plasmodium vivax DHFR and human DHFR against natural compounds has been carried out. In the present investigation, our result highlighted that; (3aS, 6S, 6aS, 9aR, 9bS)-6a-hydroxy-6, 9a-dimethyl-3-methylidene-8-pentyl-2H, 3H, 3aH, 4H, 5H, 6H, 6aH, 9H, 9aH, 9bH-azuleno [4, 5-b] furan-2,9-dione, (3aR, 6S, 6aS, 9aR, 9bR)-8-heptyl-6a-hydroxy-6, 9a-dimethyl-3-methylidene-2H, 3H, 3aH, 4H, 5H, 6H, 6aH, 9H, 9aH, 9bH-azuleno [4, 5-b] furan-2,9-dione, (3aR, 6S, 6aS, 9aR, 9bR)-8-heptyl-6a-hydroxy-6, 9a-dimethyl-3-methylidene-2H, 3H, 3aH, 4H, 5H, 6H, 6aH, 9H, 9aH, 9bH-azuleno [4, 5-b] furan-2,9-dione-2, (3S, 4S, 9bR)-3-acetyl-6-(hydroxymethyl)-3, 9-dimethyl-2, 7-dioxo-2H, 3H, 3aH, 4H, 5H, 7H, 8H, 9bH-azuleno [4, 5-b] furan-4-yl (2E)-2-methylbut-2-enoate, (3aR, 6S, 6aS, 9aR, 9bR)-8-heptyl-6a-hydroxy-6, 9a-dimethyl-3-methylidene-2H, 3H, 3aH, 4H, 5H, 6H, 6aH, 9H, 9aH, 9bH-azuleno [4, 5-b] furan-2,9-dione -3 yielded a pre-eminent dock score for with proteins human DHFR -9.3, -9.04, -9.01, -9.03, -8.93Kcal/mol respectively (Table 3) . Protein-ligand interactions delineate that the lipophilic, hydrogen bonding and π-π stacking interactions represent a central role in protein-ligand interactions at the active site. Molecular docking procedure identifies the docking free energy value (G-score) against these receptor protein molecules. Protein-ligands interactions highlighted the lipophilic, electrostatic and hydrogen bond interactions are a key player in protein-ligand interactions. All the compounds in the dataset were docked into the active site of human DHFR, using the same protocol. Figure 4 depicts the binding conformations of the parthenin like compounds in the binding pocket of the human DHFR. The active site of human DHFR comprises of mostly hydrophobic amino acids as Ile7, Ala9, Trp24, Phe31, Phe34, Thr56, Pro61, and Ile60, Val115 and these amino acid residues are involved in strong hydrophobic interactions with the parthenin like compounds. As expected, inhibitors used in this study bind to the same site like the docked ligand in the crystallographic complex. The inhibitors bind in a hydrophobic pocket adjacent to helix αB, with the 5-deazapteridine ring almost perpendicular to the 5-quinolylamino group. The 5-deazapteridine ring of the inhibitors forms hydrophobic contacts with Val8, Ile7 and Phe31. Notably, the human DHFR parthenin like compound inhibitors displayed same interaction Ile 7, Thr56 and Ile60 knowledgeable by some cycloguanil analogues which proved to be active against influenza virus and respiratory syncytial virus replication, via targeting the host (human) DHFR enzyme. 18 In another study 5-deazapteridine rings of DMDP (2, 4-diamino-5-methyl-5-deazapteridine) derivatives has been shown to bound human DHFR active site in an identical fashion, as reported in case of other inhibitors like methotrexate.
19
Recently, Viira et al. screened curcuminoids for their in silico antimalarial activity against P. falciparum and found 17 potential lead compounds, which they further tested 3aS, 6S, 6aS, 9aR, 9bS)-6a-hydroxy-6, 9a-dimethyl-3-methylidene-8-pentyl-2H, 3H, 3aH, 4H, 5H, 6H, 6aH 1KMS with (3aR, 6S, 6aS, 9aR, 9bR)-8-heptyl-6a-hydroxy-6, 9a-dimethyl-3-methylidene-2H,  3H, 3aH, 4H, 5H, 6H, 6aH, 9H, 9aH, 9bH-azuleno by using in vitro antimalarial assay and found that most of the lead compounds were potential antimalarial agents.
20
ADME/T properties of leads molecules
ADME/T properties of lead compounds ( Figure 6 ) were appraised by using the Qikprop application of Maestro 9.6
21
. Most attractive aspect of CID3467446, (6R, 6aS, 9bR)-6a-hydroxy-3-(hydroxymethyl)-6, 9a-dimethyl-4H, 5H, 6H, 9bH-azuleno [4, 5-b] furan-2,9-dione, 3467446, 56671343, (3S, 3aS, 4S, 4aS, 7aR, 8S, 9aS)-3, 4a, 8-trimethyl-2, 5-dioxo-3H, 3aH, 4H, 7aH, 8H, 9H, 9aH-azuleno [6, 5-b] furan-4-yl (3S)-3-hydroxy-2-methylidenebutanoate, 3467446, 3482907, 3467446, 3482907, 77977597 are their admirable, Qplogpo/w, QplogHERG, QplogBB, QPP MDCK, Qplogkhsa, and Percentage of human oral value which satisfy the lipinski's rule of five (Table 4) . Moreover, polar surface area, high oral bioavailability, H-bond donors and acceptors are being imperative criteria for the development of therapeutic agents. Veber et al. reported that compounds having 10 or fewer rotatable bonds and polar surface area equal to or less than 140 Å (or 12 or fewer H-bond donors and acceptors) may have a high probability for best oral bioavailability in the rat. 22 Furthermore, it is also reported that polar surface area is inversely proportional to permeation rate. 23 These compounds have better SASA values that are claimed to be suitable for therapeutic agents. These results indicate that the compounds will have better penetration rate. Blood Brain Barrier (BBB) involves biochemical barriers such as metabolic Lowest binding energy for the ligand-DHFR (PDB, 1KMS) 
-dione e* (3aR, 6S, 6aS, 9aR, 9bR)-8-heptyl-6a-hydroxy-6, 9a-dimethyl-3-methylidene-2H, 3H, 3aH, 4H, 5H, 6H, 6aH, 9H, 9aH, 9bH-azuleno [4, 5-b] furan-2,9-dione Molecule CID; Pubchem IDs, GScore; Glide extra precision scores (kcal/mol)., Lipophilic E Vdw; Chemscore lipophilic pair term and fraction of the total protein-ligand vdw energy., HBond; Hydrogen-bonding term., Electro; Electrostatic rewards., Protein ligands interaction; π-π stacking, π -cat interaction and hydrogen bond between the ligands and protein.
enzyme systems and efflux transporters for the xenobiotics. hERG (human Ether-a-go-go-Related Gene) gene codes K v 11.1 protein (α subunit of K + channel). It conducts potassium ions out of the heart muscle cells and coordinates the heart's beating. In silico human colon adenocarcinoma (Caco-2) and Madin-Darby canine kidney (MDCK) epithelial cell models are used to evaluate drug's permeability and transporter interactions. Structure-based serum albumin binding model was used to determine the distribution and metabolism of lead compounds. This encompasses the in silico binding strength of lead compounds to human serum albumin. Human oral bioavailability deals with the information about fraction of an administered drug that reaches its site of action through systematic circulation, to exert its pharmacological and therapeutic effects. All these models unscrew the qualitative prediction and ranking of absorption, determining mechanism(s) of permeability, formulation effects on drug permeability, and the potential for transporter-mediated drug-drug interactions.
CONCLUSION
In this work, molecular docking studies were carried out to explore the binding mechanism of parthenin like compounds derivatives to the P. vivax and human DHFR enzyme to enable the design of new parthenin like compound-based human DHFR inhibitors. Both the binding conformation of parthenin like compounds and their binding free energies were predicted by molecular docking. Present study can be considered as an in silico 3-acetyl-6-(hydroxymethyl)-3, 9-dimethyl-2, 7-dioxo-2H, 3H, 3aH, 4H, 5H, 7H, 8H, 9bH-azuleno [4, 5-b] furan-4-yl (2E)-2-methylbut-2-enoate can potentially be used as starting lead compound in developing anti-DHFR agents for mammals. 3S, 3aS, 4S, 4aS, 7aR,  8S, 9aS)-3, 4a, 8-trimethyl-2, 5-dioxo-3H, 3aH, 4H, 7aH, 8H, 9H, 9aH-azuleno[6, 5-b]furan-4-yl (3S)-3-hydroxy-2-methylidenebutanoate (E) (3aS, 6S, 6aS, 9aR, 9bS)-6a-hydroxy-6, 9a-dimethyl-3-methylidene-8-pentyl-2H, 3H, 3aH, 4H, 5H, 6H, 6aH, 9H, 9aH,  9bH-azuleno[4, 5-b]furan-2,9-dione (F) (3S, 4S, 9bR)-3-acetyl-6-(hydroxymethyl)-3, 9-dimethyl-2, 7-dioxo-2H, 3H, 3aH, 4H, 5H, 7H Structural analysis of docked complexes of selected parthenin like compounds with Plasmodium vivax DHFR revealed strong chances of involvement of residues like Arg115, Leu136, Lys138, and Gly175 in inhibition. In addition to amino acids Leu136, Ile155, and Val178 appeared in the hydrophobic interactions. Moreover, the active site of human DHFR comprises of mostly hydrophobic amino acids as Ile7, Ala9, Trp24, Phe31, Phe34, Thr56, Pro61, and Ile60, Val115 and these amino acid residues are involved in strong hydrophobic interactions with the parthenin like compounds. The obtained results are expected to be useful for understanding not only the mode of inhibition but also in rapid and accurate prediction of the newly designed inhibitors. We also conclude that hydrophobic forces might play a highly influencing role in inhibition of Plasmodium vivax DHFR and successfully delineate specific functional groups that might be reSsponsible for hydrophobic effect of parthenin like compounds.
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SUMMARY PICTORIAL ABSTRACT
• Parthenin like compounds has the ability to bind selectively with P. vivax dihydrofolate reductase protein. In comparison to known inhibitors (Dock Score up to -8.04), parthenin like compounds showed better Dock Score (up to -9.3). Arg 115, Leu 136, Lys 138, Gly 175, Ser 117, Gln 177 amino acid residues of P. vivax dihydrofolate reductase protein are involved in strong interactions with lead compounds. All the bestdocked lead compounds followed Lipinski's rule of five and showed drug-likeness, non-toxic, nonmutagenic and better biological properties. Thus parthenin like compounds showed possibilities to become potent anti-malarial agents of natural origin. Further in vitro and in vivo studies are required to study their potential.
